Research Meeting Presentations


Presentations from the Small Cell Lung Cancer (SCLC) Research Consortium Annual Meeting and the Consortium’s Monthly Webex Meetings are posted as a reference.

SCLC Research Consortium Annual Meetings

ISALC 2017 Small Cell Lung Cancer Meeting
March 15-17, 2017
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda
2018 Annual Small Cell Lung Cancer Consortium Meeting
March 15-16, 2018
NCI Shady Grove, Rockville, MD
Program Agenda
ISALC 2019 Small Cell Lung Cancer Meeting
April 3-5, 2019
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda
2020 Annual Small Cell Lung Cancer Consortium Meeting
March 26-27, 2020
Bethesda North Marriott Hotel & Conference Center
Details here

SCLC Monthly WebEx Meetings


“Tissue Microarray (TMA) Project” 
Afshin Dowlati, MD

Professor, Department of Medicine Division of Hematology and Oncology, School of Medicine
Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center
Case Western Reserve University 
Gary Wildey, PhD
Program Manager
Case Comprehensive Cancer Center 
Case Western Reserve University 

“RB1 Loss Drives Prostate Cancer Lineage Plasticity and Therapeutic Resistance”
Leigh Ellis, PhD

Assistant Professor, Pathology, Harvard Medical School
Assistant Professor of Pathology, Oncologic Pathology
Dana-Farber Cancer Institute, Harvard Cancer Center

“Center for Systems Biology of Small Cell Lung Cancer”
Vito Quaranta, MD

Department of Biochemistry, Professor in Biochemistry & Pharmacology 
Director of Quantitative Systems Biology Center 
Co-Director of The Center for Matrix Biology
Vanderbilt University 

“Understanding Different Subsets of Small Cell Lung Cancer”
David MacPherson, PhD

Associate Member, Human Biology Division
Associate Member, Public Health Sciences Division
Fred Hutchinson Cancer Research Center 

“Enhancing Small Cell Lung Cancer Therapy with Pharmacological Ascorbate”
Bryan Allen, MD

Associate Professor of Radiation Oncology
Carver College of Medicine 
University of Iowa Health Care

“A Tuft Cell Variant of Small Cell Lung Cancer”
Chris Vakoc, MD, PhD
CSHL Cancer Center 
Gene Regulation and Cell Proliferation 
Cold Springs Harbor Laboratory 


“Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung cancer”
Ramaswamy Govindan, MD

Anheuser Busch Endowed Chair in Medical Oncology 
Professor of Medicine, Division of Oncology 
Director, Section of Medical Oncology 
Washington University School of Medicine, Siteman Cancer Center 
Obi Griffith, PhD
Assistant Professor of Medicine, Division of Oncology 
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine, Siteman Cancer Center 
Trudy Oliver, PhD
Associate Professor, Department of Oncological Sciences, 
Cell Response and Regulation Cancer Center Program 
Huntsman Cancer Institute, University of Utah 

“Using patient-derived models to understand drug responses in SCLC “
Anna Farago, MD PhD

Assistant Professor, Medicine, Harvard Medical School
Assistant, Medicine, Massachusetts General Hospital
Dana Farber/Harvard Cancer Institute 
Benjamin Drapkin, MD, PhD
Instructor, Medicine, Massachusetts General Hospital
Nicholas Dyson, PhD
Professor of Medicine, Mary B. Saltonstall Chair in Oncology, Harvard Medical School
Geneticist, Center for Cancer Research
James and Shirley Curvey MGH Research Scholar
Scientific Director, Mass General Cancer Center

“Integrated Protometabolic Analysis Reveals Metabolic Vulnerabilities in SCLC” 
Eric Haura, MD

Director, Lung Comprehensive Research Center
Co-Program Leader, Chemical Biology and Molecular Medicine Program 
Department of Thoracic Oncology
H. Lee Moffitt Cancer Center & Research Institute

“Discovering tumor vulnerabilities linked to de-differentiation: Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies”
Thomas Graeber, PhD

Director, UCLA Metabolomic Center 
Professor, Molecular & Medical Pharmacology 
Member, Crump Institute for Molecular Imaging at UCLA
UCLA Molecular Biology Institute 

“Phenotype interactions in SCLC development and detection” 
Christine Lovly, MD, PhD

Co-Leader, Translational Research and Interventional Oncology Research Program
Associate Professor of Medicine (Hematology/Oncology)
Vanderbilt Ingram Cancer Center 
Alissa Weaver, MD, PhD
Professor, Cell and Developmental Biology & Pathology, 
Microbiology, and Immunology
VU Center for Cancer Systems Biology
Vanderbilt Ingram Cancer Center 

“Developing ASCL1 and NEUROD1 lineage oncogene targeted therapy for small cell lung cancer” 
John Minna, MD

Director, Hamon Center for Therapeutic Oncology Research, 
The Moncrief Center for Cancer Genetics,
Co-Director of the Experimental Therapeutics Program, Simmons Cancer Center 
Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology 
Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Jane Johnson, PhD
Professor and Vice Chair, Department of Neuroscience 
Shirley and William S. McIntyre Distinguished Chair in Neuroscience
UT Southwestern Medical Center

“Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLC”
Kwon-Sik Park, PhD 

Associate Professor, Microbiology, Immunology, and Cancer Biology
University of Virginia, School of Medicine

“RB1 WT SCLC and RB1 WT, KEAP1 WT, STK11 WT neuroendocrine negative LCNEC”
Dmitriy Sonkin, PhD

Computational Biologist, Computational & Systems Biology Branch
Division of Cancer Treatment & Diagnosis (DCTD)
National Cancer Institute 

SCLC Research Project Presentations